Madrigal Pharmaceuticals Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $958.4M | $180.1M | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | $6.2M | $0 | $0 | — | — | — | — |
| Gross Profit | — | $173.9M | $0 | $0 | — | — | — | — |
| Gross Margin | — | 96.5% | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $813.8M | $435.1M | $108.1M | $48.1M | $37.3M | $21.9M | $22.6M | $15.3M |
| Operating Income | $-300.1M | $-497.9M | $-380.5M | $-293.6M | $-242.5M | $-206.7M | $-95.0M | $-40.7M |
| Operating Margin | -31.3% | -276.4% | — | — | — | — | — | — |
| Interest Expense | — | — | $12.7M | $4.0M | $0 | $0 | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-288.3M | $-465.9M | $-373.6M | $-295.4M | $-241.8M | $-202.2M | $-83.9M | $-32.8M |
| Net Margin | -30.1% | -258.6% | — | — | — | — | — | — |
| EPS (Basic) | $-12.85 | $-21.90 | $-19.99 | $-17.23 | $-14.63 | $-13.09 | $-5.45 | $-2.22 |
| EPS (Diluted) | $-12.85 | $-21.90 | $-19.99 | $-17.23 | $-14.63 | $-13.09 | $-5.45 | $-2.22 |
| Shares Outstanding (Basic) | 22.4M | 21.3M | 18.7M | 17.1M | 16.5M | 15.4M | 15.4M | 15.4M |
| Shares Outstanding (Diluted) | 22.4M | 21.3M | 18.7M | 17.1M | 16.5M | 15.4M | 15.4M | 15.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |